pL-CRISPR.SFFV.tRFP Citations (4)

Originally described in: Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing.
Heckl D, Kowalczyk MS, Yudovich D, Belizaire R, Puram RV, McConkey ME, Thielke A, Aster JC, Regev A, Ebert BL Nat Biotechnol. 2014 Jun 22. doi: 10.1038/nbt.2951. PubMed Journal

---

Articles Citing pL-CRISPR.SFFV.tRFP

Articles
Safe CRISPR-Cas9 Inhibition of HIV-1 with High Specificity and Broad-Spectrum Activity by Targeting LTR NF-kappaB Binding Sites. Chung CH, Allen AG, Atkins AJ, Sullivan NT, Homan G, Costello R, Madrid R, Nonnemacher MR, Dampier W, Wigdahl B. Mol Ther Nucleic Acids. 2020 Sep 4;21:965-982. doi: 10.1016/j.omtn.2020.07.016. Epub 2020 Jul 15. PubMed
Phosphorylation of REPS1 at Ser709 by RSK attenuates the recycling of transferrin receptor. Kim SH, Cho JH, Park BO, Park BC, Kim JH, Park SG, Kim S. BMB Rep. 2021 May;54(5):272-277. PubMed
CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice. Li S, Holguin L, Burnett JC. Mol Ther Methods Clin Dev. 2022 Jan 22;24:321-331. doi: 10.1016/j.omtm.2022.01.012. eCollection 2022 Mar 10. PubMed
Hypoxia stabilizes SETDB1 to maintain genome stability. Park S, Cho JH, Kim JH, Park M, Park S, Kim SY, Kim SK, Kim K, Park SG, Park BC, Moon JH, Lee G, Kim S, Kim JA, Kim JH. Nucleic Acids Res. 2023 Nov 10;51(20):11178-11196. doi: 10.1093/nar/gkad796. PubMed

If you have published an article using this material, please email us at to have your article added to this page.